Business

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

CNBC · August 20, 2026 at 8:01 AM

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.

Read the full article on CNBC ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

More from CNBC

Tanker struck in Hormuz, raising worries over escalation, as Trump vows to hit Iran 'hard'

Venezuela grants U.S.-backed oil firm NABEP 100-year concessions for 17 oil fields, White House says

Indian PM Modi implores Putin to end Ukraine war amid U.S. tariff threat on Russian oil

‘Unusual gap’ in stock options presents investors with big opportunity, Janus Henderson says

More in Business

U.S. Navy Wants Anti-Submarine Weapon That Drones Can Fire Above Water

UFC 331 Main Event And Co-Main Opening Betting Odds And Line Movement

Indiana Pacers Will Have To Deal With First Apron Hard Cap For 2026-27

Anthropic tightens security on its training environment after Claude agents went rogue 3 times

Tanker struck in Hormuz, raising worries over escalation, as Trump vows to hit Iran 'hard'

Venezuela grants U.S.-backed oil firm NABEP 100-year concessions for 17 oil fields, White House says